Point-of-care testing (POCT) for sexually transmitted infections offers rapid, decentralised diagnostics that inform clinical decisions within a single visit. Traditionally, laboratory-based nucleic ...
LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” WALTHAM, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: ...
Diagnostics firm QuidelOrtho Corp is looking to sell its point-of-care testing unit at a valuation of $1.5 billion, the ...
The company’s focus on high accuracy POCT testing reagents aligns precisely with this demand, integrating robust quality control, innovative biochemistry, and user-centered design. Moreover, the ...
Large scale deployment of rapid, low-cost, hand-held point of care testing devices for diagnosing infectious diseases is critical for improving global health. Recent advances in engineering and ...
Point-of-care-testing for suspected COVID-19 reduces time to results and may improve infection control, suggesting these tests might have clinical advantages over widely used laboratory PCR methods.
QuidelOrtho (QDEL) is looking to sell its point-of-care testing unit at a $1.5B valuation, and private equity groups have already expressed interest in the transaction, The Financial Times reported on ...
NINGBO, ZHEJIANG, CHINA, February 3, 2026 /EINPresswire.com/ — Ningbo Qinmeng Maternal and Child Products Co., Ltd., a subsidiary of Ningbo Ciliang Import and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results